Cargando…
Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy
Huntington’s disease (HD) is an inherited, autosomal dominant, degenerative disease characterized by involuntary movements, cognitive decline, and behavioral impairment ending in death. HD is caused by an expansion in the number of CAG repeats in the huntingtin gene on chromosome 4. To date, no effe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139425/ https://www.ncbi.nlm.nih.gov/pubmed/32213859 http://dx.doi.org/10.3390/ijms21062239 |
_version_ | 1783518763159650304 |
---|---|
author | Csobonyeiova, Maria Polak, Stefan Danisovic, Lubos |
author_facet | Csobonyeiova, Maria Polak, Stefan Danisovic, Lubos |
author_sort | Csobonyeiova, Maria |
collection | PubMed |
description | Huntington’s disease (HD) is an inherited, autosomal dominant, degenerative disease characterized by involuntary movements, cognitive decline, and behavioral impairment ending in death. HD is caused by an expansion in the number of CAG repeats in the huntingtin gene on chromosome 4. To date, no effective therapy for preventing the onset or progression of the disease has been found, and many symptoms do not respond to pharmacologic treatment. However, recent results of pre-clinical trials suggest a beneficial effect of stem-cell-based therapy. Induced pluripotent stem cells (iPSCs) represent an unlimited cell source and are the most suitable among the various types of autologous stem cells due to their patient specificity and ability to differentiate into a variety of cell types both in vitro and in vivo. Furthermore, the cultivation of iPSC-derived neural cells offers the possibility of studying the etiopathology of neurodegenerative diseases, such as HD. Moreover, differentiated neural cells can organize into three-dimensional (3D) organoids, mimicking the complex architecture of the brain. In this article, we present a comprehensive review of recent HD models, the methods for differentiating HD–iPSCs into the desired neural cell types, and the progress in gene editing techniques leading toward stem-cell-based therapy. |
format | Online Article Text |
id | pubmed-7139425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71394252020-04-10 Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy Csobonyeiova, Maria Polak, Stefan Danisovic, Lubos Int J Mol Sci Review Huntington’s disease (HD) is an inherited, autosomal dominant, degenerative disease characterized by involuntary movements, cognitive decline, and behavioral impairment ending in death. HD is caused by an expansion in the number of CAG repeats in the huntingtin gene on chromosome 4. To date, no effective therapy for preventing the onset or progression of the disease has been found, and many symptoms do not respond to pharmacologic treatment. However, recent results of pre-clinical trials suggest a beneficial effect of stem-cell-based therapy. Induced pluripotent stem cells (iPSCs) represent an unlimited cell source and are the most suitable among the various types of autologous stem cells due to their patient specificity and ability to differentiate into a variety of cell types both in vitro and in vivo. Furthermore, the cultivation of iPSC-derived neural cells offers the possibility of studying the etiopathology of neurodegenerative diseases, such as HD. Moreover, differentiated neural cells can organize into three-dimensional (3D) organoids, mimicking the complex architecture of the brain. In this article, we present a comprehensive review of recent HD models, the methods for differentiating HD–iPSCs into the desired neural cell types, and the progress in gene editing techniques leading toward stem-cell-based therapy. MDPI 2020-03-24 /pmc/articles/PMC7139425/ /pubmed/32213859 http://dx.doi.org/10.3390/ijms21062239 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Csobonyeiova, Maria Polak, Stefan Danisovic, Lubos Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy |
title | Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy |
title_full | Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy |
title_fullStr | Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy |
title_full_unstemmed | Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy |
title_short | Recent Overview of the Use of iPSCs Huntington’s Disease Modeling and Therapy |
title_sort | recent overview of the use of ipscs huntington’s disease modeling and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139425/ https://www.ncbi.nlm.nih.gov/pubmed/32213859 http://dx.doi.org/10.3390/ijms21062239 |
work_keys_str_mv | AT csobonyeiovamaria recentoverviewoftheuseofipscshuntingtonsdiseasemodelingandtherapy AT polakstefan recentoverviewoftheuseofipscshuntingtonsdiseasemodelingandtherapy AT danisoviclubos recentoverviewoftheuseofipscshuntingtonsdiseasemodelingandtherapy |